Abstracts tagged "Systemic lupus erythematosus (SLE) and thrombocytopenia"

Abstract Number: 2640 • 2018 ACR/ARHP Annual Meeting
Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
María Fernanda Zavala-Miranda¹, Samuel Govea-Peláez², Ricardo Vázquez-Rodríguez², Roberto Reyna², Sandra Morales², Diana Gómez-Martín³, Jorge Alcocer-Varela³, Javier Merayo-Chalico² and Ana Barrera-Vargas², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Hematologic manifestations are found in up to 30% of SLE patients. Although splenectomy is considered an acceptable therapeutic option for both refractory thrombocytopenia and…
Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Nayef M. Kazzaz¹, Patrick S. Coit², Emily E. Lewis³, W Joseph McCune⁴, Amr H. Sawalha² and Jason S. Knight², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
Abstract Number: 728 • 2015 ACR/ARHP Annual Meeting
Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival
Bahar Artim-Esen¹, Sevil Kamali¹, Ahmet Gul¹, Lale Ocal² and Murat Inanc¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Hematologic involvement is common in patients with SLE. Thrombocytopenia and autoimmune hemolytic anemia (AIHA), prevalences of which have been reported as 10-40 % and…
Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
YU PEI CHOCK¹, DENIS WAHL² and STEPHANE ZUILY³, ¹KENT MEMORIAL HOSPITAL, WARWICK, RI, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…
Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Eugenia Enriquez Merayo¹, Maria Galindo Izquierdo², Esther Rodriguez-Almaraz³, Maria Martin Lopez², Otto Martin Olivas Vergara⁴, Patricia E. Carreira⁵ and Isabel Mateo⁶, ¹RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, ²RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ³Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ⁵Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
Abstract Number: 2506 • 2013 ACR/ARHP Annual Meeting
Systemic LUPUS Erythematosus Patients Presenting With Immune Thrombocytopenia and The Association Between Two Diseases
Omer Nuri Pamuk¹, Gulsum Emel Pamuk² and Mehmet Sevki Uyanik², ¹Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ²Hematology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: We evaluated the features of our systemic lupus erythematosus (SLE) patients who presented with immune thrombocytopenia (ITP) and compared them to other SLE patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].